Sorrento Therapeutics, Inc. (SRNE) Finalizes Private Placements worth $150 Million
On April 4, 2016, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced that it entered into definitive agreements for up to $150 million with institutional investors and Yuhan Corporation, the company’s strategic corporate partner. Most recently, the agreements escalated and were finalized on private placements of common stocks and warrants worth $150 million. Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing safe and efficient therapies for cancer and other medical requirements, as well as for autoimmune, inflammation, and oncology related diseases. In the news release, president and CEO of Sorrento Therapeutics, Inc., Dr. Henry Ji, stated, “The completion of this significant…